These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 18388514)

  • 21. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
    Ujfalussy I; Koó E; Seszták M; Gergely P
    Z Rheumatol; 2003 Apr; 62(2):155-60. PubMed ID: 12721703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination treatment strategies in early rheumatoid arthritis.
    Suresh E; Lambert CM
    Ann Rheum Dis; 2005 Sep; 64(9):1252-6. PubMed ID: 15860511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leflunomide for rheumatoid arthritis.
    Drug Ther Bull; 2000 Jul; 38(7):52-4. PubMed ID: 11027115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside.
    van der Heijden JW; Dijkmans BA; Scheper RJ; Jansen G
    Nat Clin Pract Rheumatol; 2007 Jan; 3(1):26-34. PubMed ID: 17203006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are biologics more effective than classical disease-modifying antirheumatic drugs?
    Nurmohamed MT; Dijkmans BA
    Arthritis Res Ther; 2008; 10(5):118. PubMed ID: 18828888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
    Feely MG; O'Dell JR
    Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease-modifying antirheumatic drug therapy for psoriatic arthritis.
    Salvarani C; Cantini F; Olivieri I
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S71-5. PubMed ID: 12463452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [How to effectively use methotrexate in rheumatoid arthritis?].
    Hernandez-Baldizon S
    Reumatol Clin; 2012; 8(1):42-5. PubMed ID: 22089073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease-modifying antirheumatic drugs.
    Conaghan PG; Lehmann T; Brooks P
    Curr Opin Rheumatol; 1997 May; 9(3):183-90. PubMed ID: 9204252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.
    Simone D; Nowik M; Gremese E; Ferraccioli GF
    J Rheumatol Suppl; 2015 Nov; 93():65-9. PubMed ID: 26523061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leflunomide in clinical practice. A retrospective observational study on use of leflunomide in New Zealand.
    Jagoda JS; Rajapakse CN
    Int J Rheum Dis; 2011 Oct; 14(4):340-4. PubMed ID: 22004230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis.
    Ward JR
    Am J Med; 1988 Oct; 85(4A):39-44. PubMed ID: 3052055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions.
    Abasolo L; Leon L; Rodriguez-Rodriguez L; Tobias A; Rosales Z; Maria Leal J; Castaño V; Vadillo C; Macarron P; Fontsere O; Jover JA
    Semin Arthritis Rheum; 2015 Apr; 44(5):506-513. PubMed ID: 25532946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disease-modifying antirheumatic drugs.
    Ryan L; Brooks P
    Curr Opin Rheumatol; 1999 May; 11(3):161-6. PubMed ID: 10328573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.
    Lie E; Fagerli KM; Mikkelsen K; Rødevand E; Lexberg A; Kalstad S; Uhlig T; Kvien TK
    Ann Rheum Dis; 2014 Oct; 73(10):1905-6. PubMed ID: 24989896
    [No Abstract]   [Full Text] [Related]  

  • 38. Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target.
    Pincus T; Castrejón I
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S33-40. PubMed ID: 24219039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.
    Armstrong AW; Brezinski EA; Follansbee MR; Armstrong EJ
    Curr Pharm Des; 2014; 20(4):500-12. PubMed ID: 23565631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy.
    Pincus T; O'Dell JR; Kremer JM
    Ann Intern Med; 1999 Nov; 131(10):768-74. PubMed ID: 10577301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.